The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | PANGEA: personalized treatment strategy for patients with metastatic gastroesophageal adenocarcinoma
Daniel Catenacci, MD, University of Chicago, Chicago, IL, outlines the findings of a Phase II study evalating individualized treatment strategies for patients with metastatic gastroesophageal adenocarcinoma. Individually optimizing chemotherapy, biomarker profiling, and matching of targeted therapies resuled in improved outcomes when compared to historical controls. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Daniel Catenacci, MD has received support/funding from Genentech/Roche, Eli Lilly, Merck, Daiichi Sankyo, BMS, Ono, Five Prime, Seattle Genetics, Amgen, Taiho, Astellas, Gritstone, Pieris, Zymeworks, Basilea, QED, Arcus, Foundation Medicine, Tempus, Guardant Health, Archer, and Natera.
